Imfinzi (durvalumab) - AstraZeneca
tremelimumab (CP-675206) - AstraZeneca, Pfizer
lenvatinib gel suspension (AIV007) - AiViva BioPharma
Tecentriq (atezolizumab) - Roche
Nexavar (sorafenib) - Bayer, Amgen
Avastin (bevacizumab) - Roche
Keytruda (pembrolizumab) - Merck (MSD)
Cabometyx (cabozantinib tablet) - Takeda, Exelixis, Ipsen
https://www.targetedonc.com/view/looking-toward-the-future-management-of-unresectable-hcc
 
Aug 17, 2021
 
Prev Next